BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH, Dhere T, Kraft CS, Kao D, Smith J, Le L, El-Nachef N, Kaur N, Kowsika S, Ehrlich A, Smith M, Safdar N, Misch EA, Allegretti JR, Flynn A, Kassam Z, Sharfuddin A, Vuppalanchi R, Fischer M. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant 2019;19:501-11. [PMID: 30085388 DOI: 10.1111/ajt.15058] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Porras AM, Shi Q, Zhou H, Callahan R, Montenegro-Bethancourt G, Solomons N, Brito IL. Geographic differences in gut microbiota composition impact susceptibility to enteric infection. Cell Rep 2021;36:109457. [PMID: 34320343 DOI: 10.1016/j.celrep.2021.109457] [Reference Citation Analysis]
2 Qin T, Fu J, Verkade HJ. The role of the gut microbiome in graft fibrosis after pediatric liver transplantation. Hum Genet 2021;140:709-24. [PMID: 32920649 DOI: 10.1007/s00439-020-02221-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Lee MSL, Ramakrishna B, Moss AC, Gold HS, Branch-Elliman W. Successful treatment of fulminant Clostridioides difficile infection with emergent fecal microbiota transplantation in a patient with acute myeloid leukemia and prolonged, severe neutropenia. Transpl Infect Dis 2020;22:e13216. [PMID: 31769569 DOI: 10.1111/tid.13216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wong D, Nanda N. Clostridium difficile disease in solid organ transplant recipients: a recommended treatment paradigm. Curr Opin Organ Transplant 2020;25:357-63. [PMID: 32618715 DOI: 10.1097/MOT.0000000000000778] [Reference Citation Analysis]
5 Ali H, Khurana S, Ma W, Peng Y, Jiang ZD, DuPont H, Zhang HC, Thomas AS, Okhuysen P, Wang Y. Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients. J Cancer 2021;12:6498-506. [PMID: 34659541 DOI: 10.7150/jca.59251] [Reference Citation Analysis]
6 Żebrowska P, Łaczmańska I, Łaczmański Ł. Future Directions in Reducing Gastrointestinal Disorders in Children With ASD Using Fecal Microbiota Transplantation. Front Cell Infect Microbiol 2021;11:630052. [PMID: 33718277 DOI: 10.3389/fcimb.2021.630052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Krajicek E, Bohm M, Sagi S, Fischer M. Fulminant Clostridium difficile Infection Cured by Fecal Microbiota Transplantation in a Bone Marrow Transplant Recipient With Critical Neutropenia. ACG Case Rep J 2019;6:e00198. [PMID: 31737727 DOI: 10.14309/crj.0000000000000198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Gweon TG, Lee YJ, Kim KO, Yim SK, Soh JS, Kim SY, Park JJ, Shin SY, Lee TH, Choi CH, Cho YS, Yong D, Chung JW, Lee KJ, Lee OY, Choi MG, Choi M; Gut Microbiota and Therapy Research Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea. J Neurogastroenterol Motil 2022;28:28-42. [PMID: 34980687 DOI: 10.5056/jnm21221] [Reference Citation Analysis]
9 DuPont HL, Jiang ZD, DuPont AW, Utay NS. Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation. Dig Dis Sci 2020;65:741-56. [PMID: 32008133 DOI: 10.1007/s10620-020-06102-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Park SY, Seo GS. Fecal Microbiota Transplantation: Is It Safe? Clin Endosc 2021;54:157-60. [PMID: 33827154 DOI: 10.5946/ce.2021.072] [Reference Citation Analysis]
11 Mullane KM, Dubberke ER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant 2019;33:e13564. [PMID: 31002420 DOI: 10.1111/ctr.13564] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
12 Kumar V, Fischer M. Expert opinion on fecal microbiota transplantation for the treatment of Clostridioides difficile infection and beyond. Expert Opin Biol Ther. 2020;20:73-81. [PMID: 31690143 DOI: 10.1080/14712598.2020.1689952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
13 Wu W, Shen N, Luo L, Deng Z, Chen J, Tao Y, Mo X, Cao Q. Fecal microbiota transplantation before hematopoietic stem cell transplantation in a pediatric case of chronic diarrhea with a FOXP3 mutation. Pediatr Neonatol 2021;62:172-80. [PMID: 33358585 DOI: 10.1016/j.pedneo.2020.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Cibulková I, Řehořová V, Hajer J, Duška F. Fecal Microbial Transplantation in Critically Ill Patients-Structured Review and Perspectives. Biomolecules 2021;11:1459. [PMID: 34680092 DOI: 10.3390/biom11101459] [Reference Citation Analysis]
15 Ancona G, Alagna L, Lombardi A, Palomba E, Castelli V, Renisi G, Dondossola D, Iavarone M, Muscatello A, Gori A, Bandera A. The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. Infect Immun 2021;89:e0037621. [PMID: 34460287 DOI: 10.1128/IAI.00376-21] [Reference Citation Analysis]
16 Cheng Y, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, Ghabril M, Orman E, Sashidhar S, Rogers N, Xu H, Khoruts A, Vaughn B, Kao D, Wong K, Cammarota G, Ianiro G, Dhere T, Kraft CS, Mehta N, Woodworth MH, Allegretti JR, Nativ L, Marcus J, El-nachef N, Fischer M. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clinical Gastroenterology and Hepatology 2021;19:1627-34. [DOI: 10.1016/j.cgh.2020.06.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Muhsen K, Na'amnih W, Adler A, Carmeli Y, Cohen D. Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study. Helicobacter 2020;25:e12668. [PMID: 31721371 DOI: 10.1111/hel.12668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Chaudhuri A, Goddard EA, Green M, Ardura MI. Diarrhea in the pediatric solid organ transplantation recipient: A multidisciplinary approach to diagnosis and management. Pediatr Transplant 2021;25:e13886. [PMID: 33142366 DOI: 10.1111/petr.13886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Rijkers GT, Andriessen SQ, van Overveld FJ. Death and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy. Expert Rev Anticancer Ther 2019;19:831-4. [PMID: 31592683 DOI: 10.1080/14737140.2019.1677158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Cheng YW, Fischer M. Treatment of Severe and Fulminnant Clostridioides difficile Infection. Curr Treat Options Gastroenterol 2019;17:524-33. [PMID: 31745820 DOI: 10.1007/s11938-019-00262-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Steensels S, Qiao J, Ersoy BA. Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease. Metabolites 2020;10:E283. [PMID: 32660130 DOI: 10.3390/metabo10070283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
22 Chiu CW, Tsai PJ, Lee CC, Ko WC, Hung YP. Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents. Pathogens 2021;10:649. [PMID: 34073695 DOI: 10.3390/pathogens10060649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Perler BK, Chen B, Phelps E, Allegretti JR, Fischer M, Ganapini V, Krajiceck E, Kumar V, Marcus J, Nativ L, Kelly CR. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection. J Clin Gastroenterol. 2020;54:701-706. [PMID: 32011405 DOI: 10.1097/mcg.0000000000001281] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
24 Baghai Arassi M, Zeller G, Karcher N, Zimmermann M, Toenshoff B. The gut microbiome in solid organ transplantation. Pediatr Transplant 2020;24:e13866. [PMID: 32997434 DOI: 10.1111/petr.13866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Non LR, Ince D. Infectious Gastroenteritis in Transplant Patients. Gastroenterol Clin North Am 2021;50:415-30. [PMID: 34024449 DOI: 10.1016/j.gtc.2021.02.013] [Reference Citation Analysis]
27 Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther 2019;50:1094-9. [PMID: 31612528 DOI: 10.1111/apt.15526] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
28 Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol 2021;116:647-56. [PMID: 33982930 DOI: 10.14309/ajg.0000000000001075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
29 Baunwall SMD, Dahlerup JF, Engberg JH, Erikstrup C, Helms M, Juel MA, Kjeldsen J, Nielsen HL, Nilsson AC, Rode AA, Vinter-Jensen L, Hvas CL. Danish national guideline for the treatment of Clostridioides difficile infection and use of faecal microbiota transplantation (FMT). Scand J Gastroenterol 2021;56:1056-77. [PMID: 34261379 DOI: 10.1080/00365521.2021.1922749] [Reference Citation Analysis]
30 Gurram B, Sue PK. Fecal microbiota transplantation in children: current concepts. Curr Opin Pediatr 2019;31:623-9. [PMID: 31169545 DOI: 10.1097/MOP.0000000000000787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
31 Amjad W, Qureshi W, Malik A, Singh R, Jafri SM. The outcomes of Clostridioides difficile infection in inpatient liver transplant population. Transpl Infect Dis 2021;:e13750. [PMID: 34695277 DOI: 10.1111/tid.13750] [Reference Citation Analysis]
32 Shin JH, Hays RA, Warren CA. Hospitalized Older Patients with Clostridioides difficile Infection Refractory to Conventional Antibiotic Therapy Benefit from Fecal Microbiota Transplant. Adv Geriatr Med Res 2021;3:e210012. [PMID: 34263258 DOI: 10.20900/agmr20210012] [Reference Citation Analysis]
33 Peri R, Aguilar RC, Tüffers K, Erhardt A, Link A, Ehlermann P, Angeli W, Frank T, Storr M, Glück T, Sturm A, Rosien U, Tacke F, Bachmann O, Solbach P, Stallmach A, Goeser F, Vehreschild MJ; German Clinical Microbiome Study Group (GCMSG). The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany. United European Gastroenterol J 2019;7:716-22. [PMID: 31210950 DOI: 10.1177/2050640619839918] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
34 Cebrián R, Macia-Valero A, Jati AP, Kuipers OP. Design and Expression of Specific Hybrid Lantibiotics Active Against Pathogenic Clostridium spp. Front Microbiol 2019;10:2154. [PMID: 31616392 DOI: 10.3389/fmicb.2019.02154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
35 Hernández M, Saura N, García S, Velamazán R, Abad D, Hijos G, Alfaro E, Cañamares P, Laredo V, Lorente S. Recurrent Clostridium difficile infection treated with bezlotoxumab in a liver transplant patient. Gastroenterol Hepatol 2021;44:720-1. [PMID: 33199130 DOI: 10.1016/j.gastrohep.2020.09.015] [Reference Citation Analysis]
36 Stallmach A, Steube A, Grunert P, Hartmann M, Biehl LM, Vehreschild MJGT. Fecal Microbiota Transfer. Dtsch Arztebl Int 2020;117:31-8. [PMID: 32031511 DOI: 10.3238/arztebl.2020.0031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Merrick B, Allen L, Masirah M Zain N, Forbes B, Shawcross DL, Goldenberg SD. Regulation, risk and safety of Faecal Microbiota Transplant. Infect Prev Pract 2020;2:100069. [PMID: 34316559 DOI: 10.1016/j.infpip.2020.100069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Cheng YW, Fischer M. Fecal Microbiota Transplantation for Ulcerative Colitis. Are We Ready for Primetime? Gastroenterol Clin North Am 2020;49:739-52. [PMID: 33121693 DOI: 10.1016/j.gtc.2020.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Hou J, Tang Y, Chen Y, Chen D. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy. Front Cell Infect Microbiol 2021;11:739707. [PMID: 35004341 DOI: 10.3389/fcimb.2021.739707] [Reference Citation Analysis]
40 Agrawal A, Ison MG, Danziger-Isakov L. Long-Term Infectious Complications of Kidney Transplantation. Clin J Am Soc Nephrol 2021:CJN. [PMID: 33879502 DOI: 10.2215/CJN.15971020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Adelman MW, Woodworth MH, Shaffer VO, Martin GS, Kraft CS. Critical Care Management of the Patient with Clostridioides difficile. Crit Care Med 2021;49:127-39. [PMID: 33156122 DOI: 10.1097/CCM.0000000000004739] [Reference Citation Analysis]
42 Meroni M, Longo M, Dongiovanni P. Alcohol or Gut Microbiota: Who Is the Guilty? Int J Mol Sci. 2019;20. [PMID: 31540133 DOI: 10.3390/ijms20184568] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
43 Matson V, Chervin CS, Gajewski TF. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology 2021;160:600-13. [PMID: 33253684 DOI: 10.1053/j.gastro.2020.11.041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
44 Chong PP, Koh AY. The gut microbiota in transplant patients. Blood Rev 2020;39:100614. [PMID: 31492463 DOI: 10.1016/j.blre.2019.100614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Khanna S. My Treatment Approach to Clostridioides difficile Infection. Mayo Clin Proc 2021;96:2192-204. [PMID: 34175104 DOI: 10.1016/j.mayocp.2021.03.033] [Reference Citation Analysis]
46 Cavuoto KM, Galor A, Banerjee S. Ocular Surface Microbiome Alterations Are Found in Both Eyes of Individuals With Unilateral Infectious Keratitis. Transl Vis Sci Technol 2021;10:19. [PMID: 34003904 DOI: 10.1167/tvst.10.2.19] [Reference Citation Analysis]
47 Singh T, Bedi P, Bumrah K, Singh J, Rai M, Seelam S. Updates in Treatment of Recurrent Clostridium difficile Infection. J Clin Med Res. 2019;11:465-471. [PMID: 31236163 DOI: 10.14740/jocmr3854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
48 Innes AJ, Mullish BH, Ghani R, Szydlo RM, Apperley JF, Olavarria E, Palanicawandar R, Kanfer EJ, Milojkovic D, McDonald JAK, Brannigan ET, Thursz MR, Williams HRT, Davies FJ, Marchesi JR, Pavlů J. Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. Front Cell Infect Microbiol 2021;11:684659. [PMID: 34513724 DOI: 10.3389/fcimb.2021.684659] [Reference Citation Analysis]
49 Dutta D, Lim SH. Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions. Biomark Res. 2020;8:31. [PMID: 32817793 DOI: 10.1186/s40364-020-00211-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
50 Murray TS, Herbst J. The Ethics of Fecal Microbiota Transplant as a Tool for Antimicrobial Stewardship Programs. J Law Med Ethics 2019;47:541-54. [PMID: 31957576 DOI: 10.1177/1073110519897730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Wang H, Yang F, Zhang S, Xin R, Sun Y. Genetic and environmental factors in Alzheimer's and Parkinson's diseases and promising therapeutic intervention via fecal microbiota transplantation. NPJ Parkinsons Dis 2021;7:70. [PMID: 34381040 DOI: 10.1038/s41531-021-00213-7] [Reference Citation Analysis]